You are here

  • Home
  • Archive
  • Volume 11, Issue 4
  • Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)

 

Online download statistics by month:

Online download statistics by month: April 2023 to January 2026

AbstractFullPdf
Apr 2023419419137
May 2023344347193
Jun 202320220274
Jul 202314014156
Aug 202317117158
Sep 202311411743
Oct 202310210336
Nov 202313213246
Dec 20239910162
Jan 202411411688
Feb 2024797956
Mar 2024757696
Apr 2024929380
May 2024787959
Jun 2024787948
Jul 202410410775
Aug 2024818043
Sep 20245960283
Oct 2024858564
Nov 202410210443
Dec 202411812068
Jan 2025989837
Feb 202516716830
Mar 202512412870
Apr 202512112160
May 2025757653
Jun 2025646542
Jul 2025120
Jan 2026110
Total343934702000